Potential Relmada Therapeutics, Inc. (NASDAQ:RLMD) shareholders may wish to note that the CEO & Director, Sergio Traversa, recently bought US$395k worth of stock, paying US$2.82 for each share. That certainly has us anticipating the best, especially since they thusly increased their own holding by 57%, potentially signalling some real optimism.

Check out our latest analysis for Relmada Therapeutics

Relmada Therapeutics Insider Transactions Over The Last Year

In fact, the recent purchase by Sergio Traversa was the biggest purchase of Relmada Therapeutics shares made by an insider individual in the last twelve months, according to our records. That means that an insider was happy to buy shares at around the current price of US$3.27. Of course they may have changed their mind. But this suggests they are optimistic. If someone buys shares at well below current prices, it's a good sign on balance, but keep in mind they may no longer see value. Happily, the Relmada Therapeutics insiders decided to buy shares at close to current prices.

Relmada Therapeutics insiders may have bought shares in the last year, but they didn't sell any. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

Relmada Therapeutics is not the only stock that insiders are buying. For those who like to find small cap companies at attractive valuations, this free list of growing companies with recent insider purchasing, could be just the ticket.

Insider Ownership Of Relmada Therapeutics

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests. From our data, it seems that Relmada Therapeutics insiders own 8.0% of the company, worth about US$7.3m. We do generally prefer see higher levels of insider ownership.

What Might The Insider Transactions At Relmada Therapeutics Tell Us?

The recent insider purchases are heartening. And an analysis of the transactions over the last year also gives us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. We would certainly prefer see higher levels of insider ownership but analysis of the insider transactions suggests that Relmada Therapeutics insiders are expecting a bright future. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. Our analysis shows 4 warning signs for Relmada Therapeutics (2 are significant!) and we strongly recommend you look at them before investing.